Detalles de la búsqueda
1.
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes.
Diabetes Obes Metab
; 25(5): 1351-1360, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36692230
2.
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.
Lancet
; 377(9769): 924-31, 2011 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-21396703
3.
Measurement of free GH and bioactive IGF-I in non-diabetic haemodialysis patients treated with GH for 7 days.
Nephrol Dial Transplant
; 27(11): 4211-8, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22910041
4.
In vivo and in vitro microdialysis sampling of free fatty acids.
J Pharm Biomed Anal
; 43(5): 1751-6, 2007 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-17240099
5.
Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
J Diabetes
; 8(5): 720-8, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26612062
6.
Growth hormone affects both adiposity and voluntary food intake in old and obese female rats.
Eur J Endocrinol
; 146(1): 121-8, 2002 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-11751077
7.
Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
Drugs Aging
; 30(12): 1009-18, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24170235
8.
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
Lancet Diabetes Endocrinol
; 1(2): 123-31, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24622318
9.
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
Diabetes Care
; 36(4): 858-64, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23340894
10.
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Diabetes Care
; 35(12): 2464-71, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23043166
11.
The anorectic response to growth hormone in obese rats is associated with an increased rate of lipid oxidation and decreased hypothalamic galanin.
Physiol Behav
; 102(5): 459-65, 2011 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-21168429
12.
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
Diabetes Care
; 34(3): 661-5, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21270174
13.
Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats.
Eur J Pharmacol
; 646(1-3): 38-45, 2010 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20727879
14.
Treatment of Obesity Using GH.
Metab Syndr Relat Disord
; 4(1): 57-69, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-18370772
Resultados
1 -
14
de 14
1
Próxima >
>>